Search Results
10
Everything
Search Filters
Organization
Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
March 18, 2025 16:30 ET
|
Tonix Pharmaceuticals Holding Corp.
August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years ...
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025
March 13, 2025 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a...
Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th
March 11, 2025 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a pipeline of...
Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company’s Single-Dose Mpox and Smallpox Vaccine Candidate
March 10, 2025 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
The World Health Organization (WHO) recently reaffirmed the spread of new clade Ib Mpox a public health emergency of international concern (PHEIC): second Mpox-related WHO PHEIC declaration in two...
Tonix Pharmaceuticals to Present at the 2025 Virtual Investor Summit
March 05, 2025 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a...
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia
March 04, 2025 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia TNX-102 SL demonstrated statistically significant...
Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash
February 07, 2025 08:30 ET
|
Tonix Pharmaceuticals Holding Corp.
Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026 Company is debt-free after repaying mortgage on facilities ...
Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases
February 06, 2025 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Results from the Phase 1 single ascending dose study support proceeding to develop a Phase 2 trial for the prevention of kidney transplant rejection TNX-1500 blocked the primary and secondary...
Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference
February 05, 2025 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of...
Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer
February 04, 2025 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Ms. Fogarty has served at Tonix since 2016, most recently as Executive Vice President, Product Development Tonix is Preparing for Potential Launch of TNX-102 SL for the management of fibromyalgia...